Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord Injury

NCT ID: NCT00041717

Last Updated: 2020-01-14

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

213 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-07-31

Study Completion Date

2004-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Normally, nerve fibers carry electrical impulses through the spinal cord, providing communication between the brain and the arms and legs. In people with spinal cord injury, some fibers may be destroyed at the site of injury, while others remain connected but do not work correctly to carry electrical impulses. As a result, subjects with an incomplete spinal cord injury may have spasticity which is muscle spasms or muscle stiffness that makes movement difficult. Fampridine-SR is an experimental drug that increases the ability of the nerve to conduct electrical impulses. This study will examine the effects of Fampridine-SR on moderate to severe lower-limb spasticity, as well as the effects on bodily functions such as bladder control, bowel function and sexual function. The study will also examine the possible risks of taking Fampridine-SR.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Spinal Cord Injury Muscle Spasticity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

fampridine-SR 50mg/day

Group Type ACTIVE_COMPARATOR

Fampridine-SR

Intervention Type DRUG

25mg bid (twice daily)

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fampridine-SR

25mg bid (twice daily)

Intervention Type DRUG

Placebo

Placebo

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Incomplete traumatic Spinal Cord Injury (at least 18 months prior and stable for 6 months)
* Moderate to severe lower-limb spasticity
* Able to give informed consent and willing to comply with protocol

Exclusion Criteria

* Pregnancy
* History of seizures
* Existing or history of frequent Urinary Tract Infections
* History of drug or alcohol abuse
* Allergy to pyridine-containing substances
* Received a botox injection 4 months prior to study
* Received an investigational drug within 30 days
* Previously treated with 4-aminopyridine (4-AP)
* Not on stable medication dosing in 3 weeks prior to study
* Abnormal ECG or laboratory value at screening
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Acorda Therapeutics

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Andrew Blight

Role: STUDY_DIRECTOR

Acorda Therapeutics

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Lakeshore Rehabilitation Hospital

Birmingham, Alabama, United States

Site Status

Barrow Neurological Institute

Phoenix, Arizona, United States

Site Status

Baptist Medical Center

Little Rock, Arkansas, United States

Site Status

VA Palo Alto Health Care System

Palo Alto, California, United States

Site Status

Neuro-Therapeutics, Inc

Pasadena, California, United States

Site Status

Neurology Associates, P.A.

Wilmington, Delaware, United States

Site Status

National Rehabilitation Hospital

Washington D.C., District of Columbia, United States

Site Status

Miami Center to Cure Paralysis at the Univ. of Miami School of Medicine

Miami, Florida, United States

Site Status

Rehabilitation Hospital

Sunrise, Florida, United States

Site Status

Shepherd Spinal Center

Atlanta, Georgia, United States

Site Status

Rehabilitation Institute of Chicago

Chicago, Illinois, United States

Site Status

Advocate Christ Medical Center-Dept. of Physical Medicine & Rehabilitation-EMG

Oak Lawn, Illinois, United States

Site Status

Springfield Clinic-Neuroscience Institute

Springfield, Illinois, United States

Site Status

Spaulding Rehabilitation Hospital

Boston, Massachusetts, United States

Site Status

HEALTHSOUTH Braintree Rehabilitation Hospital

Braintree, Massachusetts, United States

Site Status

HEALTHSOUTH New England Rehabilitation Hospital

Woburn, Massachusetts, United States

Site Status

Mary Free Bed Hospital & Rehabilitation Center

Grand Rapids, Michigan, United States

Site Status

Mayo Clinic

Rochester, Minnesota, United States

Site Status

Washington University School of Medicine, Div. of Rehab/Neurology

St Louis, Missouri, United States

Site Status

Montana Neuroscience

Missoula, Montana, United States

Site Status

Kessler Institute of Rehabilitation

West Orange, New Jersey, United States

Site Status

The Burke Rehabilitation Hospital

White Plains, New York, United States

Site Status

UNC Chapel Hill

Chapel Hill, North Carolina, United States

Site Status

East Carolina University

Greenville, North Carolina, United States

Site Status

Wake Forest University

Winston-Salem, North Carolina, United States

Site Status

Clinical Research Services

Bismarck, North Dakota, United States

Site Status

Drake Center

Cincinnati, Ohio, United States

Site Status

Cleveland VAMC

Cleveland, Ohio, United States

Site Status

Good Shepherd Rehabilitation

Allentown, Pennsylvania, United States

Site Status

Bryn Mawr Rehabilitation Hospital

Malvern, Pennsylvania, United States

Site Status

University of Pittsburgh

Pittsburgh, Pennsylvania, United States

Site Status

HEALTHSOUTH Harmarville Rehabilitation Hospital

Pittsburgh, Pennsylvania, United States

Site Status

Northeastern Rehabilitation Associates

Scranton, Pennsylvania, United States

Site Status

Rehabilitation Services University of Utah Hospitals and Clinics

Salt Lake City, Utah, United States

Site Status

Hampton VA Hospital

Hampton, Virginia, United States

Site Status

Richmond VA Medical Center (Hunter Holmes McGuire)

Richmond, Virginia, United States

Site Status

CAMC Health Education & Research Institute

Charleston, West Virginia, United States

Site Status

Foothills Provincial General Hospital

Calgary, Alberta, Canada

Site Status

Glenrose Rehabilitation Hospital

Edmonton, Alberta, Canada

Site Status

G.F. Strong Rehabilitation Centre

Vancouver, British Columbia, Canada

Site Status

Stan Cassidy Centre for Rehabilitation

Fredericton, New Brunswick, Canada

Site Status

QEII HSC-Nova Scotia Rehabilitation Centre

Halifax, Nova Scotia, Canada

Site Status

Parkwood Hospital Site, St. Joseph's Health Care

London, Ontario, Canada

Site Status

The Rehabilitation Centre

Ottawa, Ontario, Canada

Site Status

Toronto Rehabilitation Institute, Lyndhurst Centre

Toronto, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SCI-F301

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Phase 3 Study of Dexpramipexole in ALS
NCT01281189 COMPLETED PHASE3